Experimental Hematology & Oncology (Oct 2022)

TRIM family contribute to tumorigenesis, cancer development, and drug resistance

  • Ning Huang,
  • Xiaolin Sun,
  • Peng Li,
  • Xin liu,
  • Xuemei Zhang,
  • Qian Chen,
  • Hong Xin

DOI
https://doi.org/10.1186/s40164-022-00322-w
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 22

Abstract

Read online

Abstract The tripartite-motif (TRIM) family represents one of the largest classes of putative single protein RING-finger E3 ubiquitin ligases. TRIM family is involved in a variety of cellular signaling transductions and biological processes. TRIM family also contributes to cancer initiation, progress, and therapy resistance, exhibiting oncogenic and tumor-suppressive functions in different human cancer types. Moreover, TRIM family members have great potential to serve as biomarkers for cancer diagnosis and prognosis. In this review, we focus on the specific mechanisms of the participation of TRIM family members in tumorigenesis, and cancer development including interacting with dysregulated signaling pathways such as JAK/STAT, PI3K/AKT, TGF-β, NF-κB, Wnt/β-catenin, and p53 hub. In addition, many studies have demonstrated that the TRIM family are related to tumor resistance; modulate the epithelial–mesenchymal transition (EMT) process, and guarantee the acquisition of cancer stem cells (CSCs) phenotype. In the end, we havediscussed the potential of TRIM family members for cancer therapeutic targets.

Keywords